The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Part of paid clinical trials in Pittsburgh, Pennsylvania.
- Sponsor
- UMC Utrecht
- Study ID
- NCT04075305
- Status
- Recruiting
Conditions
- Bladder Cancer
- Bladder Neoplasm
- Brain Cancer
- Brain Tumor
- Breast Cancer
- Breast Tumor
- Esophageal Cancer
- Esophageal Neoplasm
- Esophageal Tumor
- Esophagus Cancer
- Esophagus Neoplasm
- Esophagus Tumor
- Gynecologic Cancer
- Gynecologic Tumor
- Head and Neck Cancer
- Head and Neck Neoplasms
- Head and Neck Tumor
- Liver Cancer
- Liver Metastases
- Liver Neoplasms
- Lung Cancer
- Lung Neoplasm
- Lung Tumor
- Neoplasms
- Oligometastases
- Oncology
- Pancreatic Cancer
- Pancreatic Neoplasms
- Pancreatic Tumor
- Prostate Cancer
- Prostate Neoplasm
- Prostate Tumor
- Quality of Life
- Radiation Toxicity
- Rectal Cancer
- Rectal Neoplasms
- Rectal Tumor
- Tumor
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Radiation therapy — RADIATIONRadiation therapy on the CE marked and FDA approved MR-Linac
Study Details
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.
Key Dates
- First listed
- Aug 30, 2019
- Start date
- Feb 1, 2019
- Status verified
- Jan 2026
- Primary completion
- Feb 1, 2030
- Completion
- Aug 1, 2030
Study Design
- Enrollment
- 8,000 participants (estimated)
Arms
- Arm: Brain cancer
- Arm: Lung cancer
- Arm: Esophageal cancer
- Arm: Breast Cancer
- Arm: Head and Neck Cancer
- Arm: Pancreatic cancer
- Arm: Gynecological cancer
- Arm: Rectal cancer
- Arm: Prostate cancer
- Arm: Bladder cancer
- Arm: Oligometastases
- Arm: Liver cancer
- Arm: Other types of cancer
Primary Outcome Measure
Progression-free Survival [ Time Frame: 3 months after MR-Linac treatment ]
Central Contacts
- Tessa LeerT +31 (0)88 75 63707
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Allegheny Health Network | Pittsburgh | Pennsylvania | 15212 | Tom Colonias |
| Md Anderson Cancer Center | Houston | Texas | 77030 | |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | William A Hall |
Find similar trials in Pittsburgh, PA
Nationwide
Bladder cancer trialsBrain cancer trialsBreast cancer trialsEsophageal cancer trialsHead and neck cancer trialsLiver cancer trialsLung cancer trialsPancreatic cancer trialsProstate cancer trialsColorectal cancer trialsOncology trialsUrology trialsNeuro-oncology trialsBreast oncology trialsWomen's health trialsGI oncology trialsENT trialsHepatology trialsLung oncology trialsLung disease trialsProstate oncology trialsMen's health trials
By condition
By specialty
Related Studies
- Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of LifeRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Esophageal Cancer Risk RegistryRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Detection of Genetic Markers of Lung CancerRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Genetic Determinants of Barrett's Esophagus and Esophageal AdenocarcinomaRecruiting · Case Western Reserve University · Baltimore, Maryland